Ximena Mimica1, Nora Katabi2, Marlena R McGill3, Ashley Hay4, Daniella Karassawa Zanoni5, Jatin P Shah6, Richard J Wong7, Marc A Cohen8, Snehal G Patel9, Ian Ganly10. 1. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: xisomisi@gmail.com. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: katabin@mskcc.org. 3. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: mcgillm@mskcc.org. 4. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: ash.hay@gmail.com. 5. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: karassad@mskcc.org. 6. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Oncology and Reconstructive Surgery, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Electronic address: shahj@mskcc.org. 7. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: wongr@mskcc.org. 8. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: cohenm2@mskcc.org. 9. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: patels@mskcc.org. 10. Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: ganlyi@mskcc.org.
Abstract
OBJECTIVE: Polymorphous adenocarcinoma of salivary gland (PAC) is rare. Despite being described as a low risk histology, some patients develop regional and distant metastasis. More aggressive behavior has been attributed to a PAC subcategory called cribriform adenocarcinoma of minor salivary glands (CAMSG). We examined oncological outcomes of PAC. PATIENTS AND METHODS: Fifty-seven patients with PAC were identified from an institutional database of 884 patients surgically treated for salivary gland malignancies from 1985 to 2015. Detailed histopathological analysis was performed. Survival outcomes were calculated using the Kaplan-Meier method. Factors predictive of recurrence were identified using the Cox proportional hazard method. RESULTS: Fifty-four (95%) had tumors of minor salivary gland origin; the most frequent location was the oral cavity in 41 (76%), specifically the hard palate in 32 (55%). Forty-six patients (81%) were clinical T1-T2; 3 (5%) had a clinically positive neck. Thirty-two patients (56%) were classified as PAC and 14 (25%) as CAMSG. Forty-four patients (77%) had surgery alone; 13 (23%) had surgery and postoperative radiotherapy. The 5- and 10-year overall survival and disease-specific survival were 88% and 79% and 98% and 94%, respectively (median follow up 84 [1-159] months); 5- and 10-year recurrence-free survival were 93% and 88%, respectively. Univariate analysis showed male sex, III/IV stage, and CASMG variant had increased incidence of recurrence but were not statistically significant. CONCLUSION: PAC of the salivary glands is an indolent disease with good survival outcomes. Recurrence is uncommon and tends to occur late. Long-term follow-up is indicated in patients with this disease.
OBJECTIVE: Polymorphous adenocarcinoma of salivary gland (PAC) is rare. Despite being described as a low risk histology, some patients develop regional and distant metastasis. More aggressive behavior has been attributed to a PAC subcategory called cribriform adenocarcinoma of minor salivary glands (CAMSG). We examined oncological outcomes of PAC. PATIENTS AND METHODS: Fifty-seven patients with PAC were identified from an institutional database of 884 patients surgically treated for salivary gland malignancies from 1985 to 2015. Detailed histopathological analysis was performed. Survival outcomes were calculated using the Kaplan-Meier method. Factors predictive of recurrence were identified using the Cox proportional hazard method. RESULTS: Fifty-four (95%) had tumors of minor salivary gland origin; the most frequent location was the oral cavity in 41 (76%), specifically the hard palate in 32 (55%). Forty-six patients (81%) were clinical T1-T2; 3 (5%) had a clinically positive neck. Thirty-two patients (56%) were classified as PAC and 14 (25%) as CAMSG. Forty-four patients (77%) had surgery alone; 13 (23%) had surgery and postoperative radiotherapy. The 5- and 10-year overall survival and disease-specific survival were 88% and 79% and 98% and 94%, respectively (median follow up 84 [1-159] months); 5- and 10-year recurrence-free survival were 93% and 88%, respectively. Univariate analysis showed male sex, III/IV stage, and CASMG variant had increased incidence of recurrence but were not statistically significant. CONCLUSION:PAC of the salivary glands is an indolent disease with good survival outcomes. Recurrence is uncommon and tends to occur late. Long-term follow-up is indicated in patients with this disease.
Authors: Alena Skálová; Douglas R Gnepp; James S Lewis; Jennifer L Hunt; Justin A Bishop; Henrik Hellquist; Alessandra Rinaldo; Vincent Vander Poorten; Alfio Ferlito Journal: Am J Surg Pathol Date: 2017-08 Impact factor: 6.394
Authors: Alena Skalova; Radek Sima; Jana Kaspirkova-Nemcova; Roderick H W Simpson; Goran Elmberger; Ilmo Leivo; Silvana Di Palma; Tomas Jirasek; Douglas R Gnepp; Ilan Weinreb; Bayardo Perez-Ordoñez; Petr Mukensnabl; Boris Rychly; Petr Hrabal; Michal Michal Journal: Am J Surg Pathol Date: 2011-08 Impact factor: 6.394
Authors: Alyssa M Civantos; Shreya Viswanathan; Aman Prasad; Solymar Torres Maldonado; Robert M Brody; Steven B Cannady; Jason G Newman; Rabie M Shanti; Jason A Brant; Karthik Rajasekaran Journal: Eur Arch Otorhinolaryngol Date: 2021-01-03 Impact factor: 2.503
Authors: Ximena Mimica; Marlena McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Alan Ho; Marc A Cohen; Snehal G Patel; Ian Ganly Journal: Cancer Date: 2020-02-25 Impact factor: 6.860